StockNews.com Downgrades Supernus Pharmaceuticals (NASDAQ:SUPN) to Buy

StockNews.com lowered shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a strong-buy rating to a buy rating in a research note released on Monday morning.

Separately, Cantor Fitzgerald reiterated a “neutral” rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Down 2.2 %

Shares of NASDAQ:SUPN opened at $32.33 on Monday. The company has a market cap of $1.80 billion, a PE ratio of 30.22 and a beta of 0.83. Supernus Pharmaceuticals has a fifty-two week low of $25.53 and a fifty-two week high of $40.28. The firm has a 50-day simple moving average of $35.37 and a 200 day simple moving average of $35.03.

Insider Activity at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 700 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $39.62, for a total value of $27,734.00. Following the completion of the transaction, the vice president now owns 10,149 shares of the company’s stock, valued at approximately $402,103.38. This represents a 6.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Jonathan Rubin sold 927 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the sale, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. This represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,104 shares of company stock worth $440,263 in the last ninety days. 9.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Raiffeisen Bank International AG acquired a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at $25,000. GF Fund Management CO. LTD. acquired a new stake in Supernus Pharmaceuticals in the 4th quarter valued at about $42,000. Smartleaf Asset Management LLC boosted its position in shares of Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC bought a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at about $52,000. Finally, Headlands Technologies LLC grew its stake in shares of Supernus Pharmaceuticals by 203.0% in the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock worth $55,000 after purchasing an additional 1,015 shares during the last quarter.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.